Guidance Capital Inc. Makes New $239,000 Investment in Axon Enterprise, Inc (NASDAQ:AXON)

Guidance Capital Inc. bought a new position in shares of Axon Enterprise, Inc (NASDAQ:AXON - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 455 shares of the biotechnology company's stock, valued at approximately $239,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Fourth Dimension Wealth LLC purchased a new position in Axon Enterprise in the 4th quarter worth approximately $30,000. Bartlett & CO. Wealth Management LLC grew its stake in Axon Enterprise by 132.0% in the 1st quarter. Bartlett & CO. Wealth Management LLC now owns 58 shares of the biotechnology company's stock worth $31,000 after buying an additional 33 shares in the last quarter. Catalyst Capital Advisors LLC purchased a new position in Axon Enterprise in the 1st quarter worth approximately $32,000. Alpine Bank Wealth Management purchased a new position in Axon Enterprise in the 1st quarter worth approximately $40,000. Finally, Elequin Capital LP purchased a new position in Axon Enterprise in the 4th quarter worth approximately $46,000. Institutional investors own 79.08% of the company's stock.

Axon Enterprise Trading Up 3.6%

NASDAQ:AXON traded up $25.75 during midday trading on Friday, reaching $735.01. 654,601 shares of the stock traded hands, compared to its average volume of 627,317. The company has a fifty day moving average of $763.82 and a 200 day moving average of $650.93. Axon Enterprise, Inc has a 12 month low of $279.02 and a 12 month high of $830.21. The company has a debt-to-equity ratio of 0.68, a quick ratio of 2.62 and a current ratio of 2.83. The stock has a market capitalization of $57.22 billion, a P/E ratio of 177.54, a PEG ratio of 81.93 and a beta of 1.29.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 EPS for the quarter, beating analysts' consensus estimates of $1.34 by $0.07. Axon Enterprise had a net margin of 14.86% and a return on equity of 5.81%. The company had revenue of $603.63 million during the quarter, compared to analyst estimates of $585.67 million. During the same period in the prior year, the business posted $1.15 EPS. The firm's revenue was up 31.3% compared to the same quarter last year. On average, research analysts predict that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Insiders Place Their Bets

In other Axon Enterprise news, President Joshua Isner sold 9,905 shares of the company's stock in a transaction on Wednesday, May 21st. The shares were sold at an average price of $738.03, for a total value of $7,310,187.15. Following the completion of the transaction, the president directly owned 298,809 shares in the company, valued at approximately $220,530,006.27. This represents a 3.21% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michael Garnreiter sold 5,913 shares of the company's stock in a transaction on Wednesday, June 4th. The stock was sold at an average price of $760.00, for a total transaction of $4,493,880.00. Following the completion of the transaction, the director owned 17,740 shares of the company's stock, valued at $13,482,400. This trade represents a 25.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 34,642 shares of company stock worth $25,090,528. Company insiders own 4.40% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on AXON. Wolfe Research began coverage on shares of Axon Enterprise in a research note on Monday, July 7th. They issued an "outperform" rating for the company. UBS Group began coverage on shares of Axon Enterprise in a research note on Wednesday, July 16th. They issued a "neutral" rating and a $820.00 price objective for the company. Bank of America upped their price objective on shares of Axon Enterprise from $750.00 to $895.00 and gave the company a "buy" rating in a research note on Wednesday, June 4th. JPMorgan Chase & Co. upped their price objective on shares of Axon Enterprise from $730.00 to $850.00 and gave the company an "overweight" rating in a research note on Thursday, July 17th. Finally, JMP Securities lifted their price objective on Axon Enterprise from $725.00 to $825.00 and gave the stock a "market outperform" rating in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Axon Enterprise currently has an average rating of "Moderate Buy" and a consensus target price of $772.08.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.